Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.34 |
| ▸ | HRH1 | P35367 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.30 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975708 | 0.91 | ADRA2C (0.38) | ADRA2CPTGS2HRH1HTR3APDE4D | |
| SCHEMBL9975697 | 0.91 | MAPT (0.39) | ADRA2CPTGS2HRH1HTR3APDE4D | |
| SCHEMBL16859546 | 0.90 | KDM4E (0.35) | ADRA2CPTGS2HRH1HTR3APDE4D | |
| SCHEMBL19397896 | 0.88 | ADRA2C (0.31) | ADRA2CPTGS2HRH1HTR3APDE4D | |
| SCHEMBL10381499 | 0.85 | PDE10A (0.32) | — | |
| SCHEMBL10366756 | 0.84 | PHLPP2 (0.37) | KDM4EMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL9975912 | 0.84 | PDE4D (0.31) | PDE4DKDM4EALDH1A1LMNA | |
| SCHEMBL9975777 | 0.83 | PTPRF (0.37) | ADORA1KDM4EMAPTALDH1A1MEN1 | |
| SCHEMBL15639028 | 0.83 | ADRA2C (0.39) | ADRA2CPTGS2HRH1HTR3APDE4D | |
| SCHEMBL10364962 | 0.83 | KDM4E (0.45) | ADRA2CPTGS2HRH1HTR3APDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | COCRYSTAL PHARMA, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9707215-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL, DISCOVERY, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2015-07-02 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY INC (US) | 2014-10-30 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-8771665-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL DISCOVERY, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| EP-2651906-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | Cocrystal Discovery, Inc. (US) | 2013-10-23 | — | — | EP | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-07-19 | — | — | US | disclosed |
| WO-2012083105-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012083105-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL DISCOVERY, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10426762-B2 | Inhibitors of hepatitis C virus polymerase | POLR2E, POLR2H, GTF3C3 | ADRA2C 1672/4885PTGS2 1599/4885HRH1 2877/4885 |
| US-20120183496-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | ADRA2C 1014/4885PTGS2 2342/4885HRH1 1653/4885 |
| US-20150182514-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2E, POLR2H, GTF3C3 | ADRA2C 1672/4885PTGS2 1599/4885HRH1 2877/4885 |
| US-20170273962-A1 | Inhibitors of Hepatitis C Virus Polymerase | POLR2E, POLR2H, GTF3C3 | ADRA2C 1672/4885PTGS2 1599/4885HRH1 2877/4885 |
| US-20140322165-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLR2A, POLR2B, POLR2E | ADRA2C 1014/4885PTGS2 2342/4885HRH1 1653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.